Market closed

Nektar Therapeutics/$NKTR

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Nektar Therapeutics

Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Ticker

$NKTR

Sector

Health Care

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

San Francisco, United States

Employees

137

Website

www.nektar.com

NKTR Metrics

BasicAdvanced

$166M

-

-$0.84

0.61 -

Price and volume

Market cap

$166M

Beta

0.61

52-week high

$1.93

52-week low

$0.48

Average daily volume

1.9M

Financial strength

Current ratio

4.239

Quick ratio

3.649

Long term debt to equity

377.602

Total debt to equity

421.592

Interest coverage (TTM)

-5.47%

Management effectiveness

Return on assets (TTM)

-22.64%

Return on equity (TTM)

-161.63%

Valuation

Price to revenue (TTM)

1.942

Price to book

3.85

Price to tangible book (TTM)

3.85

Price to free cash flow (TTM)

-1.017

Growth

Revenue change (TTM)

5.53%

Earnings per share change (TTM)

-46.11%

3-year revenue growth (CAGR)

-2.46%

3-year earnings per share growth (CAGR)

-32.50%

What the Analysts think about NKTR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Nektar Therapeutics stock.

NKTR Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

NKTR Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

NKTR News

AllArticlesVideos

Multiple Catalysts Ahead For Nektar Therapeutics

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NKTR

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Nektar Therapeutics stock?

Nektar Therapeutics (NKTR) has a market cap of $166M as of January 15, 2025.

What is the P/E ratio for Nektar Therapeutics stock?

The price to earnings (P/E) ratio for Nektar Therapeutics (NKTR) stock is 0 as of January 15, 2025.

Does Nektar Therapeutics stock pay dividends?

No, Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Nektar Therapeutics dividend payment date?

Nektar Therapeutics (NKTR) stock does not pay dividends to its shareholders.

What is the beta indicator for Nektar Therapeutics?

Nektar Therapeutics (NKTR) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.